logo
  

Kamada Amends GLASSIA License Agreement With Takeda - Quick Facts

Israeli biopharmaceutical company Kamada Ltd. (KMDA) announced Wednesday an amendment to the GLASSIA [Alpha1-Proteinase Inhibitor (Human)] license agreement with Japanese peer Takeda Pharmaceutical Co. Ltd. (TAK)

Pursuant to the amendment, Kamada will transfer to Takeda the GLASSIA U.S. Biologics License Application (BLA) upon completion of the transition of GLASSIA manufacturing to Takeda, expected by the end of 2021.

In consideration for the BLA transfer, Kamada will receive a $2 million payment from Takeda. In addition, the payment by Takeda of the final sales-based milestone of $5 million due to Kamada under the license agreement was accelerated and the Company anticipates it will be able to recognize this milestone during 2021.

The parties have agreed to continue to share product related information and data following the BLA transfer. There are no other material changes to the existing GLASSIA license agreement.

Kamada, as the product's innovator, continues to distribute GLASSIA outside of Takeda's territories and invests in the Alpha-1 Antitrypsin Deficiency field through continued development of the proprietary Inhaled AAT product, currently in a Phase III clinical study

GLASSIA was developed by Kamada, and the product's BLA was approved by the U.S. Food and Drug Administration in 2010. Kamada expects to receive approximately $25 million in product revenues from the supply of GLASSIA to Takeda in 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
This Black Friday and the following holiday season, retailers across the United States are urged to keep up their inventory amid expected surge in shopping as majority of Americans wait till last minute to fill their baskets, according to certain studies. A new Oracle Retail survey, which was conducted last week and presented earlier this week, showed that 66 percent of consumers were less than Eagle, Idaho -based Flagship Food Group is recalling certain TJ Farms Select brand frozen cauliflower, citing the potential to be contaminated with Listeria monocytogenes, the U.S. Food and Drug Administration said. The recall involves a limited number of cases of TJ Farms Select cauliflower that comes in 16 oz. packages with lot code 2077890089 and UPC code 75544000604-3. The U.S. Food and Drug Administration has approved Takeda Pharmaceuticals Co. Ltd.'s Livtencity (maribavir) as the first drug to treat post-transplant cytomegalovirus or CMV in adults and pediatric patients. The approval is to treat patients 12 years of age and older and weighing at least 35 kilograms with post-transplant CMV infection/disease that does not respond...
Follow RTT